VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

HVT-ND
Vaccine Information
  • Vaccine Name: HVT-ND
  • Target Pathogen: Newcastle disease virus
  • Target Disease: Newcastle disease
  • Vaccine Ontology ID: VO_0004632
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • F fusion protein gene engineering:
    • Type: Recombinant vector construction
    • Description: A turkey herpesvirus vector Newcastle disease vaccine (HVT/ND) expressing the fusion gene of Newcastle disease virus (NDV) (Esaki et al., 2013).
    • Detailed Gene Information: Click Here.
  • Vector: herpesvirus of turkey vaccine vector
  • Preparation: A turkey herpesvirus vector Newcastle disease vaccine (HVT/ND) expressing the fusion gene of Newcastle disease virus (NDV) (Esaki et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Chicken Response

  • Vaccination Protocol: Chickens were vaccinated by the in ovo route to 18-day-old embryos or by the subcutaneous route to 1-day-old chicks (Esaki et al., 2013).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Challenge was conducted using a low-virulence NDV strain (genotype II; pathotype lentogenic) via the respiratory tract each week between 1 and 5 weeks of age, in order to mimic the situation in areas where virulent NDV strains do not normally exist and low-virulence strains cause mild respiratory symptoms leading to economic losses (Esaki et al., 2013).
  • Efficacy: Partial protection was observed at 3 weeks of age, when 6 out of 10 (60%) chickens were protected. Full protection was obtained at 4 and 5 weeks of age, when 9 out of 10 (90%) and 10 out of 10 (100%) chickens were protected, respectively. Finally, protection against challenge with virulent Texas GB strain at 19 weeks of age was evaluated in commercial female layer chickens vaccinated at 1 day of age with HVT/ND. All of the vaccinated chickens were protected, while all of the challenge controls succumbed to the challenge (Esaki et al., 2013).
References
Esaki et al., 2013: Esaki M, Godoy A, Rosenberger JK, Rosenberger SC, Gardin Y, Yasuda A, Dorsey KM. Protection and antibody response caused by turkey herpesvirus vector Newcastle disease vaccine. Avian diseases. 2013; 57(4); 750-755. [PubMed: 24597117].